Display options
Cite
Herlin G, Lundell L, Ost A, et al. Quantitative assessment of (99m)tc-depreotide uptake in oesophageal cancer and precursor conditions and its reflection in immunohistochemically detected somatostatin receptors. Radiol Res Pract. 2012;2012:415616doi: 10.1155/2012/415616.
Herlin, G., Lundell, L., Ost, A., Aspelin, P., Svensson, L., & Axelsson, R. (2012). Quantitative assessment of (99m)tc-depreotide uptake in oesophageal cancer and precursor conditions and its reflection in immunohistochemically detected somatostatin receptors. Radiology research and practice, 2012415616. https://doi.org/10.1155/2012/415616
Herlin, Gunnar, et al. "Quantitative assessment of (99m)tc-depreotide uptake in oesophageal cancer and precursor conditions and its reflection in immunohistochemically detected somatostatin receptors." Radiology research and practice vol. 2012 (2012): 415616. doi: https://doi.org/10.1155/2012/415616
Herlin G, Lundell L, Ost A, Aspelin P, Svensson L, Axelsson R. Quantitative assessment of (99m)tc-depreotide uptake in oesophageal cancer and precursor conditions and its reflection in immunohistochemically detected somatostatin receptors. Radiol Res Pract. 2012;2012:415616. doi: 10.1155/2012/415616. Epub 2012 Feb 28. PMID: 22550583; PMCID: PMC3328169.
Copy Download .nbib Format: NLM
Share it on

Radiol Res Pract. 2012;2012:415616. doi: 10.1155/2012/415616. Epub 2012 Feb 28.

Quantitative assessment of (99m)tc-depreotide uptake in oesophageal cancer and precursor conditions and its reflection in immunohistochemically detected somatostatin receptors.

Radiology research and practice

Gunnar Herlin, Lars Lundell, Ake Ost, Peter Aspelin, Leif Svensson, Rimma Axelsson

Affiliations

  1. Division of Medical Imaging and Technology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, 141 86 Stockholm, Sweden.

PMID: 22550583 PMCID: PMC3328169 DOI: 10.1155/2012/415616

Abstract

Background. Somatostatin receptors (SSTRs) are over-expressed in several tumors making it possible for imaging with labelled SSTR. A previous study showed feasibility to image oesophageal cancer with SSTR analogue (99m)Tc-depreotide. Purpose. (1) To investigate expression of the SSTRs in different types of esophageal carcinoma and (2) to correlate such an expression with (99m)Tc-depreotide uptake in these lesions. Material and Methods. Total 28 patients (17 with esophageal cancer and 11 with Barrett's esophagus) were examined with (99m)Tc-depreotide scintigraphy. The SSTR2A, SSTR2B, SSTR3, and SSTR5 were analyzed immunohistochemically in the lesion samples. Results. Among the patients with adenocarcinoma 10/11 expressed different amounts of SSTRs, while SSTRs were absent in 5/6 patients with Squamous cell carcinoma (Sqcc). There was no correlation neither between the (99m)Tc-depreotide uptake and the amount of SSTRs nor between the amount of SSTRs and differentiation grade of the tumor. Conclusions. (1) SSTRs are expressed in esophageal carcinoma and more abundantly so in adenocancer specimens; (2) in vivo (99m)Tc-depreotide uptake does not obviously correlate with the immunohistochemically detection of SSTRs of different subtypes in esophageal carcinoma.

References

  1. Semin Nucl Med. 2002 Apr;32(2):84-91 - PubMed
  2. J Steroid Biochem Mol Biol. 1992 Sep;43(1-3):27-35 - PubMed
  3. Int J Mol Imaging. 2011;2011:279345 - PubMed
  4. Front Neuroendocrinol. 1999 Jul;20(3):157-98 - PubMed
  5. Cancer Biother Radiopharm. 2004 Apr;19(2):253-9 - PubMed
  6. Eur J Nucl Med Mol Imaging. 2005 Sep;32(9):1026-32 - PubMed
  7. Cancer Res. 1998 May 1;58(9):1850-9 - PubMed
  8. Endocr Rev. 1995 Aug;16(4):427-42 - PubMed
  9. Semin Nucl Med. 2002 Oct;32(4):276-92 - PubMed
  10. Acta Radiol. 2009 Oct;50(8):902-8 - PubMed
  11. Nucl Med Commun. 2006 Jun;27(6):507-14 - PubMed
  12. Eur J Nucl Med. 1994 Oct;21(10):1106-13 - PubMed
  13. Psychol Bull. 1979 Mar;86(2):420-8 - PubMed
  14. Acta Radiol. 2008 Apr;49(3):295-302 - PubMed
  15. Trends Pharmacol Sci. 1995 Mar;16(3):86-8 - PubMed

Publication Types